MX2014004473A - Imidazo [1,2-c] pirimidinas 5,7-substituidas. - Google Patents

Imidazo [1,2-c] pirimidinas 5,7-substituidas.

Info

Publication number
MX2014004473A
MX2014004473A MX2014004473A MX2014004473A MX2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A MX 2014004473 A MX2014004473 A MX 2014004473A
Authority
MX
Mexico
Prior art keywords
pyrimidines
imidazo
substituted
morbidities
malignancies
Prior art date
Application number
MX2014004473A
Other languages
English (en)
Inventor
John E Robinson
Bruno P Hache
David A Moreno
Mark Laurence Boys
Laurence E Burgess
C Todd Eary
Robert Groneberg
Darren Harvey
Erik James Hicken
Christopher F Kraser
Ellen Laird
Mark C Munson
Li Ren
Stephen T Schlachter
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of MX2014004473A publication Critical patent/MX2014004473A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos de Fórmula I; y estereoisómeros y sales farmacéuticamente aceptables de estos, donde R1, R2, R3, R4, R5, R6, X1 y X2 tienen los significados que se proporcionan en la memoria descriptiva, son inhibidores de una o más cinasas JAK y son útiles en el tratamiento de enfermedades autoinmunitarias, enfermedades inflamatorias, rechazo de órganos, tejidos y células transplantadas, así como neoplasias y trastornos hematológicos y sus comorbilidades.
MX2014004473A 2011-10-12 2012-10-09 Imidazo [1,2-c] pirimidinas 5,7-substituidas. MX2014004473A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161546426P 2011-10-12 2011-10-12
PCT/US2012/059282 WO2013055645A1 (en) 2011-10-12 2012-10-09 5,7-substituted-imidazo[1,2-c]pyrimidines

Publications (1)

Publication Number Publication Date
MX2014004473A true MX2014004473A (es) 2015-04-14

Family

ID=47071473

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004473A MX2014004473A (es) 2011-10-12 2012-10-09 Imidazo [1,2-c] pirimidinas 5,7-substituidas.

Country Status (19)

Country Link
US (1) US20140228349A1 (es)
EP (1) EP2766368A1 (es)
JP (1) JP2014528475A (es)
KR (1) KR20140076619A (es)
CN (1) CN103987713A (es)
AR (1) AR088304A1 (es)
AU (1) AU2012323399A1 (es)
BR (1) BR112014008865A2 (es)
CA (1) CA2851623A1 (es)
CL (1) CL2014000931A1 (es)
CO (1) CO6950483A2 (es)
CR (1) CR20140216A (es)
IL (1) IL231903A0 (es)
MX (1) MX2014004473A (es)
RU (1) RU2014118954A (es)
SG (1) SG11201401342VA (es)
TW (1) TW201326173A (es)
UY (1) UY34388A (es)
WO (1) WO2013055645A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds
AU2014308991B2 (en) 2013-08-21 2019-02-14 Janssen Biopharma, Inc. Antiviral compounds
WO2015032423A1 (en) * 2013-09-03 2015-03-12 Sareum Limited Pharmaceutical compounds
HUE054371T2 (hu) * 2014-12-05 2021-09-28 Array Biopharma Inc 4,6-szubsztituált pirazolo[l,5-A]pirazinok mint janus kináz inhibitorok
US10617690B2 (en) 2015-01-20 2020-04-14 Wuxi Fortune Pharmaceutical Co., Ltd JAK inhibitor
HUE044240T2 (hu) * 2015-04-29 2019-10-28 Wuxi Fortune Pharmaceutical Co Ltd Janus kináz (JAK) inhibitorok
UA118822C2 (uk) 2015-05-29 2019-03-11 Вуксі Фортуне Фармасьютікал Ко., Лтд Інгібітор янус-кінази
EP3419978B1 (en) 2016-02-24 2020-04-15 Pfizer Inc Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
GB201617871D0 (en) 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
WO2019034973A1 (en) * 2017-08-14 2019-02-21 Pfizer Inc. PYRAZOLO [1,5-A] PYRAZIN-4-YL AND RELATED DERIVATIVES
JP7083203B2 (ja) * 2018-06-06 2022-06-10 ジェングル セラピューティクス，インコーポレイテッド ピラゾロピリミジン誘導体、その用途並びに医薬組成物
WO2020063751A1 (en) * 2018-09-27 2020-04-02 Fochon Pharmaceuticals, Ltd. Substituted imidazo [1, 2-a] pyridine and [1, 2, 4] triazolo [1, 5-a] pyridine compounds as ret kinase inhibitors
CN117105933A (zh) 2018-10-31 2023-11-24 吉利德科学公司 具有hpk1抑制活性的取代的6-氮杂苯并咪唑化合物
KR102650496B1 (ko) 2018-10-31 2024-03-26 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제제로서의 치환된 6-아자벤즈이미다졸 화합물
CN111320624B (zh) * 2018-12-14 2023-05-12 中国医药研究开发中心有限公司 ***并吡啶类和咪唑并吡啶类化合物及其制备方法和医药用途
CA3136468A1 (en) * 2019-04-12 2020-10-15 Primegene (Beijing) Co., Ltd. Pyrazolopyrazine derived compounds and pharmaceutical compositions used as jak inhibitors
WO2020237025A1 (en) 2019-05-23 2020-11-26 Gilead Sciences, Inc. Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors
CN111039963B (zh) * 2019-12-31 2021-03-19 卓和药业集团有限公司 Wxfl10203614水溶性类似物及其合成方法
WO2021173476A1 (en) * 2020-02-24 2021-09-02 The Trustees Of Columbia University In The City Of New York Compounds, pharmaceutical formulations, and methods for treatment of cancer
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
US20240083900A1 (en) * 2020-11-13 2024-03-14 Biogen Ma Inc. Pyrazolo[1,5-a]pyrazine derivatives as btk inhibitors
TW202402754A (zh) 2021-03-04 2024-01-16 美商美國禮來大藥廠 Fgfr3抑制劑化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010981A1 (en) 1998-08-21 2000-03-02 Parker Hughes Institute Quinazoline derivatives
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
ES2612196T3 (es) * 2005-12-13 2017-05-12 Incyte Holdings Corporation Pirrolo[2,3-b]piridinas y pirrolo[2,3-b]pirimidinas sustituidas con heteroarilo como inhibidores de quinasas Janus
HUE026659T2 (en) * 2006-11-22 2016-07-28 Incyte Holdings Corp Imidazotriazines and imidazopyrimidines as kinase inhibitors
DE102007012645A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Substituierte Imidazo- und Triazolopyrimidine
CL2008001709A1 (es) * 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
WO2011130146A1 (en) * 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases

Also Published As

Publication number Publication date
US20140228349A1 (en) 2014-08-14
CR20140216A (es) 2014-08-21
CO6950483A2 (es) 2014-05-20
SG11201401342VA (en) 2014-09-26
RU2014118954A (ru) 2015-11-20
CN103987713A (zh) 2014-08-13
AU2012323399A1 (en) 2014-05-29
CL2014000931A1 (es) 2014-08-29
WO2013055645A1 (en) 2013-04-18
AR088304A1 (es) 2014-05-21
UY34388A (es) 2014-04-30
KR20140076619A (ko) 2014-06-20
IL231903A0 (en) 2014-05-28
JP2014528475A (ja) 2014-10-27
EP2766368A1 (en) 2014-08-20
TW201326173A (zh) 2013-07-01
CA2851623A1 (en) 2013-04-18
BR112014008865A2 (pt) 2017-04-25

Similar Documents

Publication Publication Date Title
MX2014004473A (es) Imidazo [1,2-c] pirimidinas 5,7-substituidas.
MX2012011941A (es) Imidazo [1, 2-c] pirimidinas 5, 7-substituidas como inhibidores de jak cinasas.
PH12017501032A1 (en) 4,6-SUBSTITUTED-PYRAZOLO[1,5-a]PYRAZINES AS JANUS KINASE INHIBITORS
PH12016502168A1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
UA108222C2 (xx) СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
EA201390736A1 (ru) Циклобутилзамещенные производные пирролопиридина и пирролопиримидина как ингибиторы jak
UA111756C2 (uk) Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
UA112425C2 (uk) ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ
MX2014005285A (es) Compuestos biciclicos de piperazina.
MX355852B (es) Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
MX2014005282A (es) Compuestos de 8-fluoroftalazin-1 (2h) -ona.
MX2011012353A (es) Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
MX354675B (es) Inhibidores de serina/treonina cinasa.
MX2011010449A (es) Derivados de oxadiazol.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
IN2015DN03751A (es)
MY150747A (en) Pyrido[2,3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
MX2012006822A (es) 1,7-diazacarbazoles y metodos de uso.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
MX2012002327A (es) Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
TN2012000370A1 (en) 5-alkynyl pyrimidines and their use as kinase inhibitors
TH134115B (th) การใช้สารในกลุ่มอิมิดาโซ [1,2-ซี]ไพริมิดีนที่มีการแทนที่ที่ตำแหน่งที่ 5,7 เป็นสารยับยั้ง jak ไคเนส

Legal Events

Date Code Title Description
FA Abandonment or withdrawal